share_log
Breakings ·  Oct 7 19:01
Regeneron Pharmaceuticals - Expects Q3 Results Will Include Acquired Ipr&D Charge of Sbout $56 Mln on Pre-Tax Basis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment